Evidence map›Paper›PMID 40241753›Full record

ArticleiScience2025

Rostislav Skitchenko, Zora Modrusan, Alexander Loboda, Jeffrey B Kopp, Cheryl A Winkler, Alexey Sergushichev, Namrata Gupta, Christine Stevens, Mark J Daly, Andrey Shaw and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

  • Update of
    2023
5 · Who and what money

Authors and funding

11 authors.

Rostislav SkitchenkoITMO University, St. Petersburg, Russia.
Zora ModrusanResearch Biology, Genentech Inc., San Francisco, CA, USA.
Alexander LobodaITMO University, St. Petersburg, Russia.
Jeffrey B KoppKidney Disease Section, Kidney Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH, Bethesda, MD, USA.
Cheryl A WinklerMolecular Genetic Epidemiology Studies Section, National Cancer Institute (NCI), Frederick, MD, USA.
Alexey SergushichevITMO University, St. Petersburg, Russia.
Namrata GuptaBroad Institute, Cambridge, MA, USA.
Christine StevensBroad Institute, Cambridge, MA, USA.
Mark J DalyBroad Institute, Cambridge, MA, USA.
Andrey ShawResearch Biology, Genentech Inc., San Francisco, CA, USA.
Mykyta ArtomovBroad Institute, Cambridge, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Focal segmental glomerulosclerosis (FSGS) is a leading cause of nephrotic syndrome, with an annual incidence of 24 cases per million among African-Americans and 5 per million among European-Americans in the United States. It ranks as the second most common glomerular disease in Europe and Latin America and the fifth in Asia. We conducted a case-control study involving 726 FSGS cases and 13,994 controls from diverse ethnic backgrounds, using panel sequencing of ∼2,500 podocyte-expressed genes. Rare variant association tests confirmed known risk genes (

Indexed as

Association analysisClinical syndromeHuman GeneticsQuantitative genetics

Identifiers

PMID40241753
PMCPMC12003020

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.